Citation

Oquendo MA, Chaudhury SR, Mann JJ. Arch. Suicide Res. 2005; 9(3): 237-250.

Affiliation

New York State Psychiatric Institute/Columbia University, Department of Neuroscience, New York 10032, USA. moquendo@neuron.cpmc.columbia.edu

Copyright

(Copyright © 2005, International Academy of Suicide Research, Publisher Informa - Taylor and Francis Group)

DOI

10.1080/13811110590929424

PMID

16020167

Abstract

Patients with Bipolar Disorder (BD) are at particularly high risk for both attempted and completed suicides. The period of highest risk for completed suicide is during the 2 years following discharge from a hospitalization. To date, pharmacological studies of suicidal behavior in BD have been quite limited. While strong evidence has been found regarding the anti-suicidal effects of lithium, evidence for such properties in other commonly prescribed medications for BD, including anticonvulsants, SSRIs and anti-psychotics, has been largely unexplored. Considering the high risk of suicidal acts in patients with BD, further research on the pharmacotherapy of suicidal behavior is crucial.

Language: en